Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
BUSINESS
Chugai Halts Dosing of Non-Ambulatory Patients in DMD Gene Therapy Trial after 2 Deaths Overseas
Chugai Pharmaceutical has suspended dosing in Japan of non-ambulatory patients under a global PIII trial of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene moxeparvovec) following two death cases reported overseas. Subject to the dosing suspension is a non-ambulatory…
To read the full story
Related Article
- DMD Gene Therapy Elevidys Hits Japan Market at Record Price
February 20, 2026
- DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
- Elevidys Coverage Debate to Resume after MHLW Gains Broad Understanding on Safety
October 9, 2025
- MHLW Orders Label Revision for Elevidys to Add Acute Hepatic Failure
September 1, 2025
- Chugai to Defer Domestic Supply of Elevidys amid Safety Review
July 25, 2025
- Japan Puts a Hold on Coverage Discussions for Elevidys over Safety Concerns
June 19, 2025
- Chugai’s DMD Gene Therapy Snags Conditional Approval in Japan
May 14, 2025
BUSINESS
- Vital KSK’s Medleap Pivots to In-House Drug Filings, Eyes 2029 Launch
November 10, 2026
- Alfresa, Partners Seal Share Deal to Formalize Biosimilar JV
November 10, 2026
- Japan Ethical Drug Sales Rise 3.5% in September: Crecon
November 10, 2026
- Shionogi Grabs Japan Nod for Updated COVID Vaccine
November 10, 2026
- Kyorin Nabs Japan Rights to Edesa’s ARDS Drug
November 10, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…